2 of 20 Sessions Available
-
JUN10June 10, 2020Wed 4:00 PM EDT 1HClosed
-
PAUL M. BARR, MD
-
RYAN W. JACOBS, MD
-
-
SEP01September 01, 2020Tue 4:00 PM EDT 1HClosed
-
-
-
SEP03
-
SEP08
-
OCT08
-
OCT15
-
NOV18
-
NOV19
-
NOV25
-
DEC02
-
DEC11
-
JAN12
-
JAN13
-
JAN15
-
JAN22
-
FEB09
-
FEB10
-
FEB12
-
MAR11
Contributors
-
PAUL M. BARR, MD
Medical Director, Clinical Trial Office
Associate Professor of Medicine
James P. Wilmot Cancer Institute
University of Rochester Medical Center
Rochester, NY
Paul M. Barr, MD is an Associate Professor of Medicine and the Medical Director of the Clinical Trials Office (CTO) at the James P. Wilmot Cancer Institute at the University of Rochester Medical Center. His internal medicine and hematology oncology training were completed at Case Western Reserve University; the latter supported by a National Institutes of Health (NIH)/National Cancer Institute (NCI) K12 award. Additional clinical research training was achieved through the American Society of Hematology Clinical Research Training Institute.
Dr. Barr’s research is focused on the development of novel treatment combinations for lymphoma and chronic lymphocytic leukemia. He has led several single institution, multi-center and cooperative group studies. His early research was supported by pilot grants from the Wilmot Fellowship and the Rochester NIH Specialized Program of Research Excellence Award in Lymphoma, as well as a career development grant awarded by the Lymphoma Research Foundation. Ongoing research includes: 1) defining treatment for early progressing follicular lymphoma through the National Clinical Trials Network supported SWOG 1608 trial; 2) incorporating PI3K inhibition into the treatment armamentarium through an investigator-initiated multicenter study of umbralisib, ublituximab, and venetoclax; and 3) further defining the role of first-line BTK inhibition in CLL through a single-center investigator-initiated study of an acalabrutinib-based combination.
Dr. Barr’s focus on clinical-trial design and an administrative position as the CTO Director is supported by an NCI National Clinical Trials Network Lead Academic Participating Site Award, for which he serves as Principal Investigator (PI). He also serves as University of Rochester PI for the SWOG oncology cooperative group and sits on the SWOG Board of Governors. He remains active in the Association of American Cancer Institutes, Clinical Research Initiative, having previously served on the group’s steering committee. -
RYAN W. JACOBS, MD
Principal Investigator, Lymphoma Section
Levine Cancer Institute
Atrium Health
Charlotte, NC
Ryan W. Jacobs, MD joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015 and has served as a clinician and Principal Investigator in the Lymphoma Section since that time. His clinical practice is comprised of patients with diagnoses of Hodgkin’s and non-Hodgkin’s lymphoma. Dr. Jacobs has both a clinical and research focus on patients with chronic lymphocytic leukemia (CLL). In his role as a Principal Investigator, he oversees the clinical trials conducted at LCI that involve the treatment of patients with CLL. As the CLL expert for the LCI/Atrium Health system, he is responsible for creating and overseeing the patient care pathways involving the treatment of CLL patients in a network that spans North and South Carolina.
In addition to clinical trials, Dr. Jacobs has a research interest in real-world outcomes of patients with CLL on novel therapies and has contributed to this field of research by evaluating patients across North and South Carolina treated in a variety of clinical settings. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015. Dr. Jacobs is board-certified in hematology, medical oncology, and internal medicine. Through LCI’s adjunct affiliation, Dr. Jacobs is an Assistant Professor of Medicine at the University of North Carolina, Chapel Hill.